[ad_1]
Hong Kong's first biotechnology stock is about to enter the market and, according to market information, non-profit biotechnology company Ascletis Pharma has auditioned.
According to the preliminary prospectus document published by the company, there are currently five plans for the discovery and development of antiviral drugs, including two hepatitis C drugs at the marketing stage, but it is not the case. There are no commercial products.
The losses of the company for the fiscal years 2016 and 2017 were 6.761 million yuan (RMB ‧ the same) and 132 million yuan.No product has been marketed, it n & # 39; There was no turnover during the period.
For more information on IPO and fund-raising data badysis, please visit the new Hong Kong Stocks 360 IPO page.
[ad_2]
Source link
